A total of 15 healthcare and medtech companies have raised £190m on the AIM sub-market of the London Stock Exchange since the beginning of March – despite the implications caused by the coronavirus outbreak.
The uses for the funding include clinical trials, product development, business expansion and growth strategies and underlines London public markets supporting growth strategies of healthcare and medtech despite macroeconomic uncertainty
Included in this funding is capital for Synairgen, Faron and Fusion, who are working on a potential treatment for COVID-19.
Over £789m (AIM: £357m, Main Market: £432m) has been raised by healthcare firms across London’s markets since the beginning of the year.
Marcus Stuttard, Head of UK Primary Markets & AIM, London Stock Exchange Group, said: “We are delighted to see London’s public equity markets continue to support the growth of vibrant healthcare and medtech companies. Since the launch of AIM 25 years ago, a key feature of the market has been the ability of listed firms to issue further equity, accounting for approximately 60% of money raised on AIM.
“The recent fundraisings by healthcare and medtech companies in particular demonstrates the strong funding ecosystem and the willingness of investors to fund innovation and growth, despite uncertainty caused by the pandemic. Over the coming months London’s equity and debt capital markets will continue to play a vital role by providing companies with access to much-needed capital to help navigate the COVID-19 storm.”
|Company||Total Money Raised £m||Pricing Date||Deal Specific Industry Group (SIG)|
|Avacta Group plc||4||06-Apr-20||Healthcare-Biomed/Genetics|
|C4X Discovery Holdings plc||2||07-May-20||Healthcare-Instruments|
|Diurnal Group plc||11||06-Mar-20||Healthcare-Drugs/Pharmaceuticals|
|Eden Research plc||9||18-Mar-20||Healthcare-Biomed/Genetics|
|Faron Pharmaceuticals Oy||12||22-Apr-20||Healthcare-Drugs/Pharmaceuticals|
|Fusion Antibodies plc||3||28-Apr-20||Healthcare-Biomed/Genetics|
|Horizon Discovery Group plc||7||17-Apr-20||Healthcare-Biomed/Genetics|
|Motif Bio plc||1||05-May-20||Healthcare-Biomed/Genetics|
|OptiBiotix Health plc||1||17-Apr-20||Healthcare-Biomed/Genetics|
|Polarean Imaging plc||6||13-Mar-20||Healthcare-Instruments|